Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDV3100 (enzalutamide) vs bicalutamide in castrate men with metastatic prostate cancer
2010-021868-15Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival. Started Apr 2011; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021868-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021868-15.